Raising the profile of the neglected tropical diseases

Bernard Pécoul, MD/MPH
Executive Director, DNDi
Best Science for the Most Neglected

Respond to the Needs of Patients Suffering from Neglected Diseases

- Malaria
- Visceral Leishmaniasis (VL)
- Sleeping Sickness (HAT)
- Chagas Disease
Only 21 New Drugs Developed for Neglected Diseases (1975-2004)

Tropical diseases and tuberculosis account for 12% of the global disease burden but only 1.3% of new drugs developed.

Neglected Diseases: Current Treatment Limitations

We Need Safe, Effective, Easy to Use Drugs

- Ineffective (resistance)
- Toxic
- Expensive
- Painful when delivered
- Difficult to use
- Not registered in endemic regions
- Restricted by patents

Melarsoprol  Eflornithine
DNDi’s Virtual Model Attracting Partnerships across the Globe

128 Partners Worldwide
(45% public / 55% private)

7 Founding Partners
(4 from endemic countries)
### A robust portfolio to deliver 6-8 treatments by 2014

<table>
<thead>
<tr>
<th>Discovery</th>
<th>Pre-clinical</th>
<th>Clinical</th>
<th>Available</th>
</tr>
</thead>
<tbody>
<tr>
<td>S</td>
<td>LS L0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSK (All)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kitasato Natural Substances (HAT)</td>
<td>2 HAT LO Consort: • Scynexis • Pace Univ</td>
<td>Fexinidazole (HAT)</td>
<td>NECT Nifurtimox - Eflornithine Co-Administration (HAT)</td>
</tr>
<tr>
<td>DUNDEE (VL)</td>
<td></td>
<td>Combination Therapy (VL in Asia)</td>
<td>ASMQ (Malaria) Fixed-Dose Artesunate/Mefloquine</td>
</tr>
<tr>
<td>Eskitis Natural Products (HAT)</td>
<td>VL Consort: Advisus, CDRI</td>
<td>Combination Therapy (VL in Africa)</td>
<td>ASAQ (Malaria) Fixed-Dose Artesunate/Amodialquine</td>
</tr>
<tr>
<td>IPK (VL)</td>
<td></td>
<td>Paromomycin</td>
<td></td>
</tr>
<tr>
<td>Exploratory</td>
<td></td>
<td>AmBisome</td>
<td></td>
</tr>
<tr>
<td>Screening: LSTMH, Swiss Tropical Institute, Antwerp University, Murdoch, UFOP, Fiocruz</td>
<td>8 aminoquinolines (VL) - in preparation</td>
<td>Miltefosine – in preparation</td>
<td></td>
</tr>
<tr>
<td>Chagas Consort: CDCO, Epichem, Murdoch Univ</td>
<td>Exploratory</td>
<td>Combination Therapy (VL in Latin America) – in preparation</td>
<td></td>
</tr>
<tr>
<td>6 to 8 new treatments</td>
<td></td>
<td>Pediatric Benznidazole (Chagas)</td>
<td></td>
</tr>
<tr>
<td>a robust pipeline</td>
<td></td>
<td>Azoles (Chagas)</td>
<td></td>
</tr>
</tbody>
</table>

Exploatory
3 Products already available

- **2007**
  - ASAQ (Malaria) Fixed-Dose Artesunate/Amodiaquine

- **2008**
  - ASMQ (Malaria) Fixed-Dose Artesunate/Mefloquine

- **2009**
  - NECT Nifurtimox - Eflornithine Co-Administration (HAT)

**Partners**
- sanofi-aventis (France)
- Farmanguinhos (Brazil)
- Cipla (India)
- National Control Programs
- MSF
- WHO

- Easy to Use
- Affordable
- Field-Adapted
- Non-Patented
Funding Diversity

$150M of $350M Secured (2004-2014)

Projected Commitments

Private Donors
- Bill & Melinda Gates Foundation
- MSF
- Other Private Foundations

Public Donors
- European Union
- France
- Germany
- Italy
- Netherlands
- Spain
- Switzerland
- UK
- USA - NIH

Independence through diversified sources of funding (50% from public sector & 50% from private sector)
Ensuring Sustainability Via Public Leadership & Private Contributions

- Establish **agenda** and **R&D priorities** (implementation of WHO’s Global Action Plan)
- Significantly invest with **sustainable funding**
- **Access to knowledge** and new science for R&D
- Allow **rapid approval & delivery** and devise **new IP management policies** to encourage needs-driven R&D
- **Transfer technology** and **strengthen research capacities** in developing countries
By working in a creative way, we can bring together innovation to neglected patients!

www.dndi.org